A person-centred approach to persistent HIV viraemia and drug resistance

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the real-world challenges of managing HIV viraemia and drug resistance. The argumentation is strong, grounded in clinical experience and recent local data. The use of case studies effectively illustrates the complexity of adherence issues and the need for a holistic approach. The introduction of dolutegravir drug exposure testing as a triage tool is a practical and evidence-based suggestion. The speaker’s emphasis on person-centred care is well-argued, though it may be seen as idealistic in resource-limited settings. The argumentation is coherent and persuasive, though it relies heavily on anecdotal evidence from the presenter’s own practice.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigour in its use of recent data and guidelines, such as the modeling study by Lucy and colleagues and the pilot study by Dr. Kim Steegen. However, specific references are not provided in the video, and the speaker does not cite sources directly. The title accurately reflects the content, focusing on a person-centred approach to persistent viraemia and drug resistance. The content is well-structured and clinically relevant, but the lack of explicit citations may limit its verifiability. The speaker’s expertise is evident, and the information is consistent with current HIV management guidelines.

The title accurately reflects the content, focusing on a person-centred approach to persistent viraemia and drug resistance.

8/10

Presentation by an experienced clinician, grounded in clinical cases and recent local data, but lacks detailed references and peer-reviewed citations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the problem of persistent viraemia and drug resistance in South Africa.
• 05:00Discussion on the scale of unsuppressed patients and the impact of dolutegravir resistance.
• 10:00Explanation of the mechanism of drug resistance using the 'broken copy machine' analogy.
• 15:00Introduction of dolutegravir drug exposure testing as a triage tool.
• 20:00Case 1: 51-year-old male with work-related adherence issues and dolutegravir resistance.
• 25:00Case 2: 53-year-old male with structural barriers, including mobility and incarceration.
• 30:00Case 3: Elderly woman with mental health issues and polypharmacy leading to resistance.
• 35:00Case 4: 28-year-old perinatally infected man with long-term adherence challenges and suicidal ideation.
• 40:00Case 5: Discussion of the importance of person-centred care and its principles.
• 45:00Conclusion: Call for a shift towards person-centred care to improve outcomes.

• Dolutegravir drug exposure testing pilot study — Mentioned as a pilot study by Dr. Kim Steegen, showing that absence of DTG in blood correlates with low resistance prevalence.
• Modeling study on dolutegravir resistance — Mentioned as a modeling study by Lucy and colleagues, predicting 42% dolutegravir resistance within a decade if suppression is not achieved.

• WHO HIV drug resistance report — Supports the concern about increasing HIV drug resistance globally.
• Person-centred care in HIV — Aligns with the presenter's emphasis on person-centred care as a key component of HIV management.

• Potential limitations of drug exposure testing — The presenter notes that some patients with undetectable drug levels may still have resistance, as seen in Case 3, indicating a potential limitation of the triage tool.